Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International publ : strengthens management team

12/06/2019 | 02:01am EST

Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.

"Henrik possesses a rare combination of scientific expertise and commercial experience. With his many years of diagnostics background, he brings with him tremendous insight and an extensive network of contacts. Henrik is an important piece of the puzzle in Biovica's continued market expansion," said Anders Rylander, CEO of Biovica.

Winther has previously worked as Global VP of Business Development at the Danish diagnostics company Dako and later as General Manager of the Companion Diagnostic (CDx) Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen. He will start at Biovica on November 18.

"For a decade, Companion Diagnostics i.e. patient stratification for the right individualized treatment has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalized cancer medicine is the monitoring of patient response to therapy," said Winther.

"Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level," he said.

Audiocast
When:                          6 December 2019 at 10.00 CET
Where:                            https://tv.streamfabriken.com/biovica-international-q2-2019 or
                                     SE: +46850558369 / DK: +4578150107 / UK: +443333009261 / US: +18335268384
Broadcast language:  in English

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica - Best Treatment from Day One
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-strengthens-management-team,c2984506

https://mb.cision.com/Main/14910/2984506/1157110.pdf

https://news.cision.com/biovica-international-ab/i/henrik-winther-bw-s,c2725238

(c) 2019 Cision. All rights reserved., source Press Releases - English

All news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTum«TKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum«TK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTum«TKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum«TKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum«TKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTum«TKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,60 M -4,60 M
Net cash 2021 134 M 15,9 M 15,9 M
P/E ratio 2021 -31,8x
Yield 2021 -
Capitalization 1 253 M 149 M 150 M
EV / Sales 2021 373x
EV / Sales 2022 26,2x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 44,30 SEK
Spread / Highest target 133%
Spread / Average Target 51,2%
Spread / Lowest Target -30,0%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors